In a phase 3 trial, researchers determined if weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel with respect to overall survival in patients requiring second-line treatment for advanced gastric cancer.
Adding the mesenchymal-epithelial transition (MET) antibody onartuzumab did not significantly improve clinical outcomes.
This fact sheet explores the links, both negative and positive, that Helicobacter pylori may have with gastric and other cancer types.
First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine (B-DOC) plus maintenance therapy was feasible and active.
Chemosensory and food-related changes significantly impacted food preferences and had practical and social consequences.
Certain drugs currently used to treat breast, ovarian, and pancreatic cancers could also be used to treat certain gastric cancers with a particular genomic molecular fingerprint.
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer.
The heliobacter pylori bacterium is the main cause of stomach ulcers, and it also a known risk factor for non-cardia gastric cancer.
The anti-PD-1 monoclonal antibody, pembrolizumab (MK-3475), demonstrated promising antitumor activity in advanced gastric cancer, according to a study presented at the 2015 ASCO Annual Meeting.
Nutrition support might be helpful to improve the prognosis of patients with stage IV gastric cancer.
Precise risk assessment for gastric and breast cancers among CDH1 gene mutation carriers may improve genetic counselingFebruary 24, 2015
More exacting estimates of age-associated risks of gastric and breast cancer were derived for carriers of the CDH1 gene mutation, a cancer-predisposing gene in families meeting criteria for clinically defined hereditary diffuse gastric cancer.
Researchers found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.
In a recent study, researchers found that by taking a daily aspirin, the incidence of gastrointestinal cancers is reduced, as well as a reduction in cancer-specific mortality.
Scientists have identified the cancer-specific stem cell that causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.
Adolescents' weight and socioeconomic status (SES) may affect their subsequent risk of developing esophageal and gastric cancer, according to a study.
An investigational drug improved median survival while reducing risk of disease progression or death in persons with metastatic gastric cancer participating in the phase III REGARD trial.
Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.
Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to new research.
Meta-analysis shows lower odds of gastric cancer for highest versus lowest intake of dietary fiber.
Recently, researchers analyzed metastatic gastric cancer cases from the SEER database to help determine which treatment options offer the best survival possibilities.
Persons with metastatic gastric cancer who had both surgery and radiation lived longer than patients who underwent one or neither treatment.
A nutritional education program for patients with gastrectomy improved knowledge, oral intake, adherence to diet guidelines, and patient satisfaction compared with patients who received usual nutrition education.
A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.
Clinical Trial: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (CatuNeo)May 29, 2012
Patients with gastric cancer who undergo resection show survival benefit 10 years later.
Results from three new studies are consistent with earlier findings that aspirin can reduce cancer risk and, in some cases, metastasis.
Aspirin use lowers the risk of esophageal, gastric, biliary, and breast cancer and reduces distant metastases.
With the exception of lung cancer in women and pancreatic cancer, mortality from major cancers is expected to decline in the European Union in 2012.
The FDA has expanded approval to children for a breath test that screens for Helicobacter pylori, a cause of ulcers, gastritis, and certain cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|